We are building a pipeline of in vivo and ex vivo therapies, as well as continuing to develop innovative modular platform capabilities.
In Vivo CRISPR is the therapy
Genetic DiseasesPreclinical
Clinical
Clinical
- AATD: alpha-1 antitrypsin deficiency
- Lead refers to lead development and commercial party
- * Intellia is advancing both wholly-owned and partnered programs.
- ** Hemophilia A program is in the research stage.
Ex Vivo CRISPR creates the therapy
Immuno-Oncology / Autoimmune DiseasePreclinical
Clinical
Clinical
- * Intellia is advancing both wholly-owned and partnered programs.